GlobeNewswire Inc.··NaSeres Therapeutics Demonstrates SER-155 Promise in Transplant Patients at ESCMID
Seres Therapeutics presented Phase 1b data for SER-155 showing microbiome shifts and reduced infections in transplant patients at ESCMID Global 2026.
MCRBallogeneic hematopoietic cell transplantationPhase 1b trial